Extent to which Novartis's Tasigna will replace Gleevec uncertain
This article was originally published in Scrip
Executive Summary
Detailed results of the Phase III first-line head-to-head trial of Novartis's Tasigna (nilotinib), its follow-on to Gleevec (imatinib), reveal a lower rate of progression to advanced chronic myeloid leukaemia (CML) with Tasigna, but questions remain over the extent to which it may replace the highly effective older drug in newly diagnosed disease.